{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.59","upperLimit":"25.79","value":"13.5"},{"groupId":"OG001","lowerLimit":"3.76","upperLimit":"20.51","value":"10.0"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"28.49","value":"0.0"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.59","upperLimit":"25.79","value":"13.5"},{"groupId":"OG001","lowerLimit":"5.94","upperLimit":"24.59","value":"13.3"},{"groupId":"OG002","lowerLimit":"0.23","upperLimit":"41.28","value":"9.1"}]}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.88","upperLimit":"28.08","value":"15.4"},{"groupId":"OG001","lowerLimit":"8.29","upperLimit":"28.52","value":"16.7"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"28.49","value":"0.0"}]}],"title":"Week 36"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"Core phase - Percentage of patients achieving GH \\<1μg/L at week 12, 24, 36 overall and by GH level at screening.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who were diabetic in the Pasireotide LAR overall group","id":"OG000","title":"Diabetic"},{"description":"Participants who were pre-diabetic in the Pasireotide LAR overall group","id":"OG001","title":"Pre-diabetic"},{"description":"Participants who were non-diabetic in the Pasireotide LAR overall group","id":"OG002","title":"Non-diabetic"}],"paramType":"NUMBER","populationDescription":"FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.","reportingStatus":"POSTED","timeFrame":"Weeks 12, 24 & 36","title":"Core Phase: Percentage of Participants With Mean GH <1 μg/L and IGF-1 <ULN Overall by Baseline Diabetic Status","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}